[Hormonal changes in buserelin therapy].
Buserelin has been applied intranasal in 31 women of the reproductive age for endometriosis that had been diagnosed by laparoscopic and bioptic means. The treatment period was 6 month and hormonal changes were evaluated after 2, 4, 8, 12, 17, 20, and 24 weeks. After 2 weeks we observed a decrease of FSH to the lower normogonadotropic range, and of progesteron to less than 0.5 ng/ml. After 4 weeks LH decreased to the lower normogonadotropic range and E2 was below 55 pg/ml. Prolactin concentrations varied between 6 and 8 ng/ml.
Fuchs
U
U
Universität-Frauenklinik Tübingen.
Zwirner
M
M
D000328:Adult; D002064:Buserelin / Q000627:therapeutic use*; D004715:Endometriosis / Q000097:blood / Q000188:drug therapy*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D005833:Genital Neoplasms, Female / Q000097:blood / Q000188:drug therapy*; D012739:Gonadal Steroid Hormones / Q000097:blood*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood
D012739:Gonadal Steroid Hormones; D011374:Progesterone; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin
Hormonelle Veränderungen unter Buserelintherapie.